Search - tctmd.com

Displaying 41 - 59 of 59

Sort: Relevancy | Date

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

L.A. McKeown

August 21, 2019

News Industry News

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

July 23, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Industry News

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

April 16, 2019

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Daily News

Biomarkers, New Data, and Revised Methods Boost Accuracy of the ACC/AHA Risk Equations

Todd Neale

June 04, 2018

News Daily News

High-Sensitivity Troponin May Help Uncover Heart Failure Risk

Todd Neale

January 11, 2018

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Conference News AHA 2016

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

Todd Neale

November 13, 2016

News Conference News ESC 2016

New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study

Shelley Wood

August 27, 2016

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

News Industry News

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

October 26, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Conference News ESC 2015

Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients

L.A. McKeown

August 31, 2015

News Industry News

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

August 26, 2015

News Conference News Cell Therapy 2012

Novel Strategies Advance Cell Therapy for Cardiomyopathy

February 05, 2012

Advertisement

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Biomarkers, New Data, and Revised Methods Boost Accuracy of the ACC/AHA Risk Equations

High-Sensitivity Troponin May Help Uncover Heart Failure Risk

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

Novel Strategies Advance Cell Therapy for Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content